

RESEARCH

Open Access



Retrospective audit of 957 consecutive ^{18}F -FDG PET–CT scans compared to CT and MRI in 493 patients with different histological subtypes of bone and soft tissue sarcoma

Ruth E. Macpherson^{1,2}, Sarah Pratap^{1,3}, Helen Tyrrell³, Mehrdad Khonsari², Shaun Wilson^{1,5}, Max Gibbons^{1,4}, Duncan Whitwell^{1,4}, Henk Giele^{1,4}, Paul Critchley^{1,4}, Lucy Cogswell^{1,4}, Sally Trent^{1,3}, Nick Athanasou^{1,4,6}, Kevin M. Bradley^{1,2} and A. Bassim Hassan^{1,3,6*}

Abstract

Background: The use of ^{18}F -FDG PET–CT (PET–CT) is widespread in many cancer types compared to sarcoma. We report a large retrospective audit of PET–CT in bone and soft tissue sarcoma with varied grade in a single multi-disciplinary centre. We also sought to answer three questions. Firstly, the correlation between sarcoma sub-type and grade with ^{18}F -FDG SUVmax, secondly, the practical uses of PET–CT in the clinical setting of staging (during initial diagnosis), restaging (new baseline prior to definitive intervention) and treatment response. Finally, we also attempted to evaluate the potential additional benefit of PET–CT over concurrent conventional CT and MRI.

Methods: A total of 957 consecutive PET–CT scans were performed in a single supra-regional centre in 493 sarcoma patients (excluding GIST) between 2007 and 2014. We compared, PET–CT SUVmax values in relation to histology and FNCCC grading. We compared PET–CT findings relative to concurrent conventional imaging (MRI and CT) in staging, restaging and treatment responses.

Results: High-grade (II/III) bone and soft tissue sarcoma correlated with high SUVmax, especially undifferentiated pleomorphic sarcoma, leiomyosarcoma, translocation induced sarcomas (Ewing, synovial, alveolar rhabdomyosarcoma), de-differentiated liposarcoma and osteosarcoma. Lower SUVmax values were observed in sarcomas of low histological grade (grade I), and in rare subtypes of intermediate grade soft tissue sarcoma (e.g. alveolar soft part sarcoma and solitary fibrous tumour). SUVmax variation was noted in malignant peripheral nerve sheath tumours, compared to the histologically benign plexiform neurofibroma, whereas PET–CT could clearly differentiate low from high-grade chondrosarcoma. We identified added utility of PET–CT in addition to MRI and CT in high-grade sarcoma of bone and soft tissues. An estimated 21% overall potential benefit was observed for PET–CT over CT/MRI, and in particular, in ‘upstaging’ of high-grade disease (from M0 to M1) where an additional 12% of cases were deemed M1 following PET–CT.

Conclusions: PET–CT in high-grade bone and soft tissue sarcoma can add significant benefit to routine CT/MRI staging. Further prospective and multi-centre evaluation of PET–CT is warranted to determine the actual predictive value

*Correspondence: bass.hassan@path.ox.ac.uk

⁶ NIHR Musculoskeletal Biomedical Research Unit (Sarcoma Theme), Sarcoma and TYA Unit of the NHS Oncology Department, and Sir William Dunn School of Pathology, University of Oxford, South Parks Road, Oxford OX1 3RE, UK

Full list of author information is available at the end of the article

and cost-effectiveness of PET–CT in directing clinical management of clinically complex and heterogeneous high-grade sarcomas.

Keywords: Sarcoma, Positron emission tomography, Multi-disciplinary, Staging, Therapeutic response

Background

Conventional cross-sectional imaging techniques are routinely applied to the diagnostic and staging imaging of bone and soft tissue sarcomas, e.g. CT and MRI [1–3]. Diagnostic review of biopsies and staging scans in supra-regional multi-disciplinary teams (MDT), aims to inform clinical management in line with national and international sarcoma guidelines. MRI is also generally performed to guide local staging and restaging following neo-adjuvant therapy, whereas in subsequent post-treatment follow-up, high resolution CT is primarily used for the detection of distant metastases, particularly in the lung. As primary curative treatment for sarcoma is mostly surgical, accurate staging is essential in order to minimize inappropriate interventions in the presence of metastatic disease.

Combined ^{18}F -FDG Positron Emission Tomography with CT (PET–CT) offers potential advantages with respect to sarcoma, as it provides both metabolic and anatomical imaging combined in a single examination. Sarcomas are frequently large tumours (>5 cm) with intra-tumour regional and cellular heterogeneity, and frequently in larger tumours, central necrosis associated with hypoxia. As mesenchymal derived cancers, sarcomas may be detected by ^{18}F FDG uptake because of the general high metabolic activity and insulin sensitivity of these tissues. The maximum standardized uptake value (SUVmax) of ^{18}F FDG into higher-grade sarcoma appears to correlate with mitotic count and grade in some reported series [4, 5], and potentially with overall prognosis [6–10]. Reporting response assessment to oncological therapies using SUVmax before and after treatment, may also better correlate with histological response compared to dimensions alone [11]. With the advent of new systemic therapies that are either cytostatic or immunomodulatory, PET–CT has additional potential advantages in assessing responses depending on the therapeutic mechanism.

Despite these potential advantages, there have been relatively few reported series, with low cases numbers, providing information on which to base the routine application of functional PET–CT in specialist sarcoma clinical practice [12–20]. Moreover, in rare (<6 per 100,000 population) sarcoma subtypes (approximately 80 different molecular based diagnostic subtypes in the WHO classification 2013), there appears even less ‘real world’ reported evidence for the application of PET–CT. Here,

we retrospectively audit consecutively performed PET–CT scans in a supra-regional sarcoma centre. We initially attempted to address three questions; the correlation between histological sub-type and grade with ^{18}F FDG uptake; the use of PET–CT in the clinical setting of staging (during initial diagnosis), restaging (new baseline prior to definitive intervention) and treatment response, and the potential additional benefit obtained from PET–CT over concurrent conventional CT and MRI imaging in these settings.

Methods

Patient database

Retrospective audit of consecutive ^{18}F FDG PET–CT scans from one supra-regional UK sarcoma centre (Multi-disciplinary team, Oxford Sarcoma Service, Oxford University Hospitals Foundation Trust, UK) occurred between 1st February 2007 and 25th June 2014. The radiology search for scans was independently cross-referenced with the Oxford Sarcoma Service (OxSarc) sarcoma database (2006–2014) for diagnosis and outcome, to ensure that patients had been captured on both systems. The histological subtype and grade of each sarcoma was confirmed by pathology review and accessed via the local EPR system. Grade I sarcoma were regarded as low-grade, and grade II and III sarcoma as high-grade. All imaging (MRI, CT and PET–CT) were performed as directed either by the MDT, or were performed just prior to referral by an external clinician, with the information obtained used for consensus MDT agreement for subsequent clinical management. Thus, all scans performed and reported here were approved by the MDT specialist sarcoma team, and were therefore driven either as a result of the initial histology result of the biopsy, or appearances of local imaging of the presenting mass etc.

Imaging procedures

PET–CT imaging from June 2007 to 2nd November 2009 was performed on a GE Discovery (STE BGO 16 slice CT, 400 MBq ^{18}F FDG, 60 min uptake period, fixed 80 mA/140 kV for CT, 4 min per bed position) and from 3rd November 2009, on a GE Discovery 690 (LYSO time of flight) 64 slice CT, 4 MBq/kg ^{18}F FDG, 90 min uptake period, modulated mA based on noise index ($n=25$) 120 kV, 4 min per bed position). All scans included the skull base to either the upper thigh, or at least the joint below primary disease in the lower limbs where required,

and included the head in skull or head and neck disease. Patients were fasted with a standard procedure for at least 6 h prior to the PET–CT. All the PET–CT examinations were independently reported by two consultant radiologists subspecializing in nuclear medicine and PET–CT, and were re-reviewed by a post CCT radiologist subspecializing in nuclear medicine/PET (RM) as part of this evaluation alongside the verified reports.

For the purpose of assessing the correlation between sarcoma grade and disease avidity, the FDG avidity calculated as standardized uptake value (SUVmax) on each PET–CT was recorded. SUVmax is simply the decay corrected maximum tracer activity (^{18}F FDG) within a volume of interest (VOI) and is available on all PET–CT scans. The standardized uptake value is $(\text{SUV}) = [\text{VOI activity concentration}] / [\text{injected activity} / \text{Weight g/mL}]$, and if 1 mL of tissue volume is taken to weigh 1 g, then it becomes unit-less. The most FDG avid focus site of disease, whether primary or metastatic, was utilized as the SUVmax. In those cases where the SUVmax was not documented, this was re-calculated using standard GE supplied PET–CT analysis software. If there was CT evidence of a disease site however, with the FDG uptake at or below background (mediastinal blood pool) levels i.e. sites that are FDG essentially negative, the FDG avidity was documented as equal to 1.

Imaging evaluation

All ^{18}F FDG PET–CT and conventional imaging modalities (CT and MRI) were re-analyzed with respect to sarcoma diagnostic sub-type, the timing and purpose of the scan with respect to staging, restaging or treatment response. The differences in sarcoma disease distribution between the ^{18}F FDG PET–CT and conventional MRI/CT scans were documented if scans were performed within 4 weeks of each other, otherwise any differences were not reported for the purpose of this evaluation. Not all patients had all types of scan within 4 weeks of each other, and so comparisons are necessarily retrospective and cannot be formally evaluated beyond descriptive reporting. For bone and pulmonary metastatic sites that were identified by PET–CT, the non-contrast enhanced CT components of the scan were examined separately and considered as the ‘conventional’ CT imaging modality. For soft tissue sites, including abdominal and pelvic sites, comparisons were made between ^{18}F FDG PET–CT and either separate contrast enhanced CT scans or MRI scans where possible. The specific ^{18}F FDG PET–CT advantages over conventional imaging were also determined for occult and solitary disease in either visceral, bone, muscular, sub-cutaneous and nodal sites. Histopathology was undertaken using standard diagnostic pathway with UK sarcoma reference pathologist (NA), using

conventional WHO international guidelines (2012) and French based staging system (FNCCC). For the assessment of additional potential advantages of PET–CT, this was only conferred once histological data was reviewed to determine whether ‘PET positive’ disease had been histologically proven, or, if sampling had not been undertaken, where there was imaging evidence of progression over time confirming the presence of malignant disease, except for the common incidental unrelated sites in the colon, thyroid, prostate and breast.

Statistical analysis

Descriptive statistics using Prism 7.0a were applied, including ANOVA and non-parametric Mann–Whitney tests. Sensitivity, specificity, positive predictive value and negative predictive values were calculated by standard means.

Results

Over the 7-year period of the audit evaluation, a total of 493 patients (age range 15–91, median 55 years) referred to the Oxford MDT with histologically confirmed sarcoma, underwent a total of 957 PET–CT scans during their course of management. The number of patients within sarcoma sub-types, the number of PET–CT studies performed and the clinical indications for performing PET–CT are shown (Table 1, Fig. 1). Most PET–CT scans were performed in high-grade ($n = 930$) versus low-grade sarcoma ($n = 27$, e.g. low grade chondrosarcoma and low grade soft tissue sarcoma), with a wide distribution of histological subtypes that reflect the distribution of referred cases (shown are where there were > 4 cases per histological subtype, Fig. 1). PET–CT scans were usually performed as a result of MDT decisions, usually in the context of patients that were being planned to undergo radical treatments, such as radical surgery, and where the scan was for initial staging and exclusion of metastatic disease (36% of scans). All of these cases had concurrent MRI and CT imaging already, mainly for local staging and exclusion of lung metastasis. In this staging population, a further 12% (42/344) then had detectable metastatic disease overall by PET–CT that was not detected by conventional CT/MRI. Re-staging with a new baseline scan occurred in cases with suspected later relapse, prior to potential further radical and salvage treatment (39% of scans), and assessment of treatment response to therapeutics in the remaining (35% of scans, see Table 1).

A statistically significant difference was observed between mean SUVmax of high and of low-grade sarcoma independent of histological subtype (p value < 0.0001 , Fig. 2). Most high-grade sarcomas had mean SUVmax values greater than 10, with wide distribution of SUVmax activity rather than a defined cut-off,

Table 1 Number of patients, PET-CTs and indication for PET-CTs according to sarcoma subtype


Sarcoma pathological diagnosis	Number of patients	Number of PET-CT scans			
		Total	Staging ^a (with metastasis)	Restaging	Treatment response
Undifferentiated pleomorphic ^b	81	166	64 (6)	62	40
Angiosarcoma ^c	8	11	7 (1)	3	1
Leiomyosarcoma	89	166	43 (8)	84	39
Rhabdomyosarcoma	16	53	13 (4)	15	25
Myxofibrosarcoma	21	30	14 (2)	8	8
Epithelioid sarcoma	10	23	7 (1)	15	1
Osteosarcoma	48	98	39 (7)	28	31
Clear cell sarcoma	6	8	5 (1)	3	0
Ewing sarcoma/DSRCT	31	120	20 (6)	47	53
Synovial sarcoma	26	44	17 (3)	24	3
De-differentiated liposarcoma	18	36	11 (1)	17	8
Solitary fibrous tumour	14	25	8 (1)	9	8
Chondrosarcoma grade 2/3	24	45	18 (1)	17	10
Myxoid/round cell liposarcoma	26	36	18 (4)	12	6
Alveolar soft part sarcoma	4	4	4 (1)	0	0
MPNST	37	65	33 (4)	21	11
Low grade soft tissue sarcoma	25	17	17 (0)	0	0
Chondrosarcoma grade 1	9	10	6 (0)	4	0
Total	493	957	344 (51)	369	244


DSRCT desmoplastic small round cell sarcoma, MPNST malignant peripheral nerve sheath tumour, includes low-grade

^a Note this is overall detection of metastatic disease at initial CT and MRI staging only, 'added value' comparison is reported in Table 3

^b Includes high grade 'spindle cell sarcoma'

^c Includes 'high grade epithelioid haemangioendothelioma'






making the distinction within grade and between histological subtypes more subtle (Fig. 2). Importantly, between the specific low and high-grade subtypes, there appeared significant differences in SUVmax that presumably reflects the differential mechanisms of cellular derangement (Fig. 3a). For the example of chondrosarcoma, the differences between low and high-grade defined histologically also appeared to threshold at the SUVmax value of 4 (Fig. 3b), whereas in MPNST, the spectrum of SUVmax values significantly overlapped depending on the histological classification, making any distinction of grade based on SUVmax less discriminative and less correlative with histology (Fig. 3c). A further factor in relation to SUVmax distribution and histology also includes the anatomical origin of otherwise identical histologies, exemplified by leiomyosarcoma, with an apparent higher SUVmax observed in gynaecological compared to non-gynaecological (vascular) origin leiomyosarcoma (Fig. 3d).

As a result of intra-tumoural heterogeneity, differences in SUVmax between sarcoma sites within each patient


may be manifest at different stages of the disease. SUVmax values were compared between scans performed at primary staging, with those performed later in follow-up in relapse. The expectation was that more aggressive cell types would have populated relapse disease sites compared to the primary tumour, and potentially be reflected in a higher SUVmax in those relapsed sites. Subsequent comparison of the highest SUVmax per scan at primary staging and restaging, grouped by sarcoma histological subtype, revealed no statistically significant differences (Figs. 4), although in some subtypes, trends in SUVmax values may be increasing, e.g. in leiomyosarcoma.

Of the 930 PET-CT scans performed in high-grade sarcoma, 193 displayed features considered to have added value over conventional CT and/or MRI performed concurrently (21%, Table 2). Of these 193 PET-CT scans, 56 were performed at initial sarcoma diagnostic staging, 78 at re-staging (new baselines) and 59 in treatment (chemotherapy) responses (Table 2). Here, 'added value' refers to any additional specific features offered by PET-CT. Specifically, added value does not only relate to the



identification of further metastatic disease sites in addition to those already identified by the conventional CT and MRI imaging, but to those features resulting in so-called ‘upstaging’ of disease. For example, PET-CT specific detection of either occult muscular and soft tissue metastases, small peritoneal or other visceral metastases not visualized by conventional non-contrast enhanced CT (as part of PET-CT) and MRI imaging (Table 3, see examples in Fig. 5). Thus, ‘added value’ of PET-CT reflects detection of metastatic disease (M1) in patients who would be otherwise staged as M0 by conventional imaging approaches. In patients with high-grade sarcoma, it was possible to compare a total of 284 PET-CT scans with the conventional CT and MRI specifically during the initial diagnostic staging. In terms of the presence or absence of metastatic disease (M0 versus M1),

of these, 232 patients were true negatives for metastatic disease (negative in both PET-CT and the conventional imaging), 24 were true positive (positive in both PET-CT and the conventional imaging), 23 were false negatives (positively identified disease in PET-CT) and 1 was a false positive (non-disease associated FDG uptake). This retrospective data results in an overall metastatic disease rate of 10% based on conventional CT and MRI, and 22% for detection with dual modality PET-CT. As both CT and PET should both be able to detect the predominant sites of pulmonary metastatic disease, this additional benefit might be expected to be mainly because of detection of non-pulmonary metastatic disease sites. Following scrutiny of these staging PET-CTs, ‘added value’ was indeed associated with detection of occult metastatic sites in bone, muscle and visceral sites, accounting for the




PET-CT upstaging (Table 3). Overall, given the prevalence of sarcoma sub-types in this bone and soft tissue sarcoma series, and compared to conventional MRI/CT, PET-CT appeared to have a greater sensitivity (96% vs 54%), positive predictive value (96%) and negative predictive value (99%), even though these sensitivity and specificity values were not prospectively evaluated.

Moreover, ‘added value’ also relates to altered FDG avidity in static sized lesions, either indicating increased SUVmax suggesting disease presence or progression, and decreased SUVmax, as a reflection of responses to oncological treatment. In this context, PET-CT specifically might have ‘added value’ in the characterization of enlarged FDG negative loco-regional lymph nodes that are likely reactive rather than sarcoma containing, and in the detection of FDG avid lesions near prostheses following reconstructive surgery, where MRI and CT artifacts preclude accurate assessment (Table 3). These findings

overall are therefore relevant both to achieving accurate TNM staging, but also to directly influence clinical decision-making for subsequent radical surgical, radiotherapy and chemotherapy interventions.

In terms of histological sub-types, the highest overall ‘added value’ appeared in the context of malignant peripheral nerve sheath tumour subtype of sarcoma (41.6%), whereas in most cases of myxofibrosarcoma and solitary fibrous tumour, the advantages of PET-CT were manifest during follow-up re-staging and treatment response assessment (Table 2). For chemo-sensitive sarcoma, ‘added value’ was skewed towards the chemotherapy treatment response assessment scans (e.g. in chemotherapy responsive rhabdomyosarcoma and Ewing sarcoma), and following trabectedin chemotherapy, such as in leiomyosarcoma (Table 2) [21]. For diagnostic staging and re-staging, significant ‘added value’ reasons also included identification of local recurrence sites at and



near prostheses (18/138), during the follow up of FDG positive lesions (17/138), for all lesions missed (not easily visible) by conventional imaging (16/138), for intra-lesional heterogeneity to guide diagnostic biopsies (16/138), and for occult (not previously visible) bone metastasis (13/138).

Discussion

Here we report a retrospective audit and evaluation of PET-CT clinical use in a single tertiary UK sarcoma center. The data represents one of the largest reported series of PET-CT use in routine sarcoma clinical practice, but this does not represent a definitive, prospective, clinical and cost effective evaluation. Despite these caveats, the use of PET-CT in this report does appear in line with evolving guidelines, including the most recent 2016

Royal College of Radiologists, UK guidelines for PET-CT in sarcoma [22]. As such, it provides valuable preliminary evidence on which to base future multi-center evaluation in a routine clinical practice, as a clinical research tool, and in the development of evidence suitable for supporting appropriate reimbursement.

In sarcoma, oncogenic drivers frequently result in up-regulation of glucose transporters, such as GLUT4 [23], resulting in higher ^{18}F FDG SUVmax levels associated with aggressive cell behavior, and when there is associated immune cell infiltration, such as in giant cell tumour of bone [24]. As expected, we observed statistically significant differences of mean SUVmax between low-grade and high-grade sarcoma histological sub-types. Moreover, significant variation in SUVmax was observed between different patients who had the same sarcoma

Table 2 Number of PET–CTs in which ‘added value’ was detected compared to conventional imaging (MRI/CT) according to sarcoma subtype

Sarcoma pathological diagnosis	Percentage of PET–CT with added value	Number of PET–CT with added value over MRI/CT		
		Staging	Restaging	Treatment response
Undifferentiated pleomorphic ^a	13.3% (22/166)	6	11	5
Angiosarcoma ^b	9% (1/11)	1	0	0
Leiomyosarcoma	18% (30/166)	7	14	9
Rhabdomyosarcoma	24.6% (13/53)	3	2	8
Myxofibrosarcoma	26.7% (8/30)	0	5	3
Epithelioid sarcoma	13% (3/23)	1	2	0
Osteosarcoma	23.5% (23/98)	6	9	8
Clear cell sarcoma	12.5% (1/8)	1	0	0
Ewing sarcoma/DSRCT	27.5% (33/120)	7	12	14
Synovial sarcoma	13.6% (6/44)	3	2	1
De-differentiated liposarcoma	8.3% (3/36)	1	1	1
Solitary fibrous tumour	28% (7/25)	0	5	2
Chondrosarcoma grade 2/3	24.4% (11/45)	3	5	3
Myxoid/round cell liposarcoma	11.1% (4/36)	2	1	1
Alveolar soft part sarcoma	25% (1/4)	1	0	0
MPNST	41.6% (27/65)	14	9	4
Low grade soft tissue sarcoma	0% (0/17)	0	0	0
Chondrosarcoma grade 1	0% (0/10)	0	0	0
Total	21% (193/930)	56	78	59

DSRCT desmoplastic small round cell sarcoma, MPNST malignant peripheral nerve sheath tumour, includes low-grade

^a Includes high grade ‘spindle cell sarcoma’

^b Includes ‘high grade epithelioid haemangiioendothelioma’

sub-type. The latter probably reflects the functional heterogeneity within the tumour and its associated micro-environment, indicating that between sarcoma subtypes, primary and metastatic disease, there are differences in SUVmax that reflect those at the molecular, cellular and micro-environment level. PET–CT appeared useful in identifying sarcoma sites that contained both high and low- grade elements (the extremes of heterogeneity), for example in de-differentiated liposarcoma, de-differentiated chondrosarcoma and in MPNST. SUVmax values > 5 were consistent with higher-grade disease, except in the case of MPNST, where there was much less correlation of SUVmax with histological assessment of grade. Thus, low-grade soft tissue sarcoma and low-grade bone sarcoma (e.g. chondrosarcoma) do not probably warrant routine PET–CT estaging valuation, unless there is clinical suspicion of high-grade transformation, such as in either large axial or pelvic chondrosarcoma.

The additional benefits (“added value”) of PET–CT appeared to be in a range of clinical contexts, making specific comparisons and overall evaluation more complex. Here we attempted to simply compare conventional CT and MRI scans performed concurrently with the PET–CT, in order to scope the scenarios that might

justify PET–CT as a routine dual scanning modality, and that impacts on potentially clinically important features. What we have not been able to fully assess in all circumstances, is to prospectively prove that direct and important changes to subsequent clinical management of patients ensued as a result of the PET–CT results, and the PET–CT results alone. For example, there can be no doubt from the radiological and clinical point of view, that the ‘added value’ of PET–CT in upstaging of disease from M0 to M1 would have had clinical impact that might make the difference between either reconstructing a limb, resecting a tumour or amputation. In this regard, our evidence suggests that whole body PET–CT has particular utility in detection of occult non-pulmonary disease not visible on conventional CT and MRI. As both CT and PET should both be able to detect the predominant sites of pulmonary metastatic disease, scrutiny of these staging PET–CTs for ‘added value’ was indeed associated with detection of occult metastatic sites in bone, muscle and visceral sites, accounting for the PET–CT upstaging. Moreover, ‘added value’ to guiding biopsies to active and viable areas of the tumour, thereby avoiding regions of necrosis, and in the post-operative setting, where MRI artifacts near metallic prostheses prevents

Table 3 Summary of the ‘added value’ features of PET–CT compared to conventional imaging (MRI and CT)

Reasons for added value of PET–CT over conventional imaging	Number of PET–CT scans per indication		
	Staging ^b	Restaging ^a	Treatment response
Occult bone metastases	10	3	1
Recurrence at local site or adjacent to metallic prosthesis not definitive on conventional imaging	0	18	2
Follow up of occult bone metastases	0	8	10
Occult muscular metastases	3	0	0
Follow up of occult muscular metastases	0	3	2
Cardiac metastases (muscular) not detected on conventional imaging	2	1	0
Subcentimetre FDG avid nodes	5	2	1
Static tumoural size, reduced FDG avidity	0	7	16
Static tumoural size, increased FDG avidity	6	2	6
Solitary FDG avid pulmonary nodule, indeterminate on CT	7	3	0
Missed visceral disease on CT/MRI	11	5	5
Metastasis outside the fields of conventional imaging	1	0	0
FDG negative suspected recurrence adjacent to prosthesis or locally in patient with prior markedly avid disease	0	3	2
Intra-lesional heterogeneity—guided biopsy to avoid underestimation of grade	10	6	0
Enlarged FDG negative nodes with moderately FDG avid primary	1	2	0
Increase in tumoural size but reduced avidity	0	0	7
Recurrence at an ablation or surgical site, indeterminate on MRI	0	2	0
Follow up of FDG positive disease adjacent to prosthesis or local surgical site	0	13	7
Total	56	78	59

^a Restaging = new baseline imaging prior to new clinical management intervention

^b Actual number of M0 to M1 upstaging = 25

adequate visualization of potential local recurrence, are also bona fide reasons to adopt PET–CT [8, 25, 26]. Conversely, inflammation related ¹⁸FDG avid foci in PET–CT studies immediately following surgery, chemotherapy and radiotherapy, can be mistaken for tumour deposits, and can be miss-interpreted by inexperienced reporting, resulting in false positives.

The choice of imaging is therefore a significant consideration when determining the timing of assessment, and may bias the subsequent reporting of results in this study. In the treatment response assessment, PET–CT addresses the discrepancy between the change in lesion size and metabolic response, and was the commonest reason for “added value” of PET–CT over conventional imaging in our series. In the staging and re-staging groups, occult metastatic disease and FDG avid nodal disease, which were not enlarged by CT criteria, may have led to improved TNM staging accuracy overall. Likewise, the presence of new sites of disease (occult disease) in the standardized dimension assessment of oncological treatment response, also indicates the need to stop current treatment and to re-evaluate alternative strategies. Whilst the staging and later findings related to ‘added value’ are based on comparison of imaging modalities performed within a few weeks, and whilst some

sarcomas may rapidly grow over such a time frame, these cases are very rare, and so we believe that the comparison period is valid.

The heterogeneity of the behavior of sarcoma cells points to the potential for high-grade cell types with more aggressive features to populate recurrent sites of disease detected at restaging. SUVmax alone does not, however, constitute a complete analysis of heterogeneity, and this question requires further analyses, as the overall ¹⁸FDG distribution within tumours has not been assessed. Further prospective validation of PET–CT in sarcoma is justified, as ‘added value’ components may also reflect differences in reporting experience and protocols. To eliminate future bias, the prospective evaluation of conventional imaging compared with PET–CT across institutions will require standardized reporting (independent double blind reporting) for both modalities. Moreover, quantification of patient outcomes with respect to changes in clinical management would need to be prospectively compared, as well as staging accuracy and cost effectiveness for the patient pathway. In summary, PET–CT in high-grade sarcoma offers the prospect additional benefit in routine staging of high-grade sarcoma at baseline, and specific staging situations during relapse and treatment.

Conclusion

We report a large retrospective audit of PET–CT in bone and soft tissue sarcoma with varied grade in a single multi-disciplinary centre. A total of 957 consecutive PET–CT scans were performed in a single supra-regional centre in 493 sarcoma patients (excluding GIST) between 2007 and 2014. High-grade (II/III) bone and soft tissue sarcoma correlated with high SUVmax, especially undifferentiated pleomorphic sarcoma, leiomyosarcoma, translocation induced sarcomas (Ewing, synovial, alveolar rhabdomyosarcoma), de-differentiated liposarcoma and osteosarcoma. We identified added utility of PET–CT in addition to MRI and CT in high-grade sarcoma of bone and soft tissues. An estimated 21% overall potential benefit was observed for PET–CT over CT/MRI, and in particular, in ‘upstaging’ of high-grade disease (from M0 to M1) where an additional 12% of cases were deemed M1 following PET–CT. This large study suggests PET–CT in high-grade bone and soft tissue sarcoma can add significant benefit to routine CT/MRI staging. Further prospective and multi-centre evaluation of PET–CT is warranted to determine the actual predictive value and cost-effectiveness of PET–CT in directing clinical management of clinically complex and heterogeneous high-grade sarcomas.

Authors' contributions

REM, SP, KMB and ABH conceived the study. REM performed data analysis of PET–CT comparison with CT/MRI. REM, SP, HT and NA assessed databases and confirmed diagnostic subtypes/grade. REM, MK and KMB reported and evaluated PET–CT scans. SP, SW, MG, DW, PC, LC, ST, KMB and ABH evaluated PET–CT as part of the Oxford Sarcoma MDT. REM, KMB and ABH wrote the paper, all authors made comments. All authors read and approved the final manuscript.

Author details

¹ Oxford Sarcoma Service (OxSarC), Oxford University Hospitals Foundation Trust, Oxford OX3 7LE, UK. ² Department of Radiology, Oxford University Hospitals Foundation Trust, Oxford OX3 7LE, UK. ³ Department of Oncology, Churchill Hospital, Oxford University Hospitals Foundation Trust, Oxford OX3 7LE, UK. ⁴ Nuffield Orthopaedic Centre, Oxford University Hospitals Foundation Trust, Oxford OX3 7LE, UK. ⁵ Department of Paediatric Oncology, Oxford University Hospitals Foundation Trust, Oxford OX3 7LE, UK. ⁶ NIHR Musculoskeletal Biomedical Research Unit (Sarcoma Theme), Sarcoma and TYA Unit of the NHS Oncology Department, and Sir William Dunn School of Pathology, University of Oxford, South Parks Road, Oxford OX1 3RE, UK.

Acknowledgements

We thank all sarcoma patients and staff at Oxford University Hospitals Trust and Oxford Sarcoma Service.

Competing interests

The authors have no competing interests with respect to this publication. KB and ABH have worked with GE healthcare in PET–CT image analysis and MDT pilot software, respectively.

Availability of data

The data that support the findings of this study are available from OUHT, but restrictions apply to the availability of these data as part of the NHS electronic patient record, which were used under anonymised consent for the current study, and so are not publicly available. Data are however available from the authors upon reasonable request and with permission of OUHT.

Ethics approval and consent to participate

All participants were diagnosed and treated in the Oxford University Hospitals Trust (OUHT), and underwent specific institutional consent for diagnostic biopsies, surgery, radiotherapy and chemotherapy. All patients are not routinely consented for cross-sectional imaging or PET–CT scans in OUHT. As part of the institutional consents, however, all patients consent for research and audit, including evaluation of tissue and all anonymised clinical data, including its presentation for publication.

Funding

We thank OUHT and NIHR BRC2 for support (SP, ABH).

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 2 November 2017 Accepted: 26 February 2018

Published online: 17 May 2018

References

- Holzapfel K, Regler J, Baum T, Rechl H, Specht K, Haller B, von Eisenhart-Rothe R, Gradinger R, Rummeny EJ, Woertler K. Local staging of soft-tissue sarcoma: emphasis on assessment of neurovascular encasement-value of MR imaging in 174 confirmed cases. *Radiology*. 2015;275:501–9.
- Tzeng CW, Smith JK, Heslin MJ. Soft tissue sarcoma: preoperative and postoperative imaging for staging. *Surg Oncol Clin N Am*. 2007;16:389–402.
- Bloem JL, Taminiau AH, Eulderink F, Hermans J, Pauwels EK. Radiologic staging of primary bone sarcoma: MR imaging, scintigraphy, angiography, and CT correlated with pathologic examination. *Radiology*. 1988;169:805–10.
- Rakheja R, Makis W, Skamene S, Nahal A, Brimo F, Azoulay L, Assayag J, Turcotte R, Hickeson M. Correlating metabolic activity on 18F-FDG PET/CT with histopathologic characteristics of osseous and soft-tissue sarcomas: a retrospective review of 136 patients. *AJR Am J Roentgenol*. 2012;198:1409–16.
- Charest M, Hickeson M, Lisbona R, Novales-Diaz JA, Derbeykan V, Turcotte RE. FDG PET/CT imaging in primary osseous and soft tissue sarcomas: a retrospective review of 212 cases. *Eur J Nucl Med Mol Imaging*. 2009;36:1944–51.
- Schwarzbach MH, Hinz U, Dimitrakopoulou-Strauss A, Willeke F, Cardona S, Mechttersheimer G, Lehnert T, Strauss LG, Herfarth C, Buchler MW. Prognostic significance of preoperative [18-F] fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging in patients with resectable soft tissue sarcomas. *Ann Surg*. 2005;241:286–94.
- Adler LP, Blair HF, Makley JT, Williams RP, Joyce MJ, Leisure G, Al-Kaisi N, Miraldi F. Noninvasive grading of musculoskeletal tumors using PET. *J Nucl Med*. 1991;32:1508–12.
- Ioannidis JP, Lau J. 18F-FDG PET for the diagnosis and grading of soft-tissue sarcoma: a meta-analysis. *J Nucl Med*. 2003;44:717–24.
- Fuglo HM, Jorgensen SM, Loft A, Hovgaard D, Petersen MM. The diagnostic and prognostic value of (18)F-FDG PET/CT in the initial assessment of high-grade bone and soft tissue sarcoma. A retrospective study of 89 patients. *Eur J Nucl Med Mol Imaging*. 2012;39:1416–24.
- Herrmann K, Benz MR, Czernin J, Allen-Auerbach MS, Tap WD, Dry SM, Schuster T, Eckardt JJ, Phelps ME, Weber WA, Eilber FC. 18F-FDG-PET/CT Imaging as an early survival predictor in patients with primary high-grade soft tissue sarcomas undergoing neoadjuvant therapy. *Clin Cancer Res*. 2012;18:2024–31.
- Evilevitch V, Weber WA, Tap WD, Allen-Auerbach M, Chow K, Nelson SD, Eilber FR, Eckardt JJ, Elashoff RM, Phelps ME, Czernin J, Eilber FC. Reduction of glucose metabolic activity is more accurate than change in size at predicting histopathologic response to neoadjuvant therapy in high-grade soft-tissue sarcomas. *Clin Cancer Res*. 2008;14:715–20.

12. Sheikhbahaei S, Marcus C, Hafezi-Nejad N, Taghipour M, Subramaniam RM. Value of FDG PET/CT in patient management and outcome of skeletal and soft tissue sarcomas. *PET Clin*. 2015;10:375–93.
13. Quartuccio N, Fox J, Kuk D, Wexler LH, Baldari S, Cistaro A, Schoder H. Pediatric bone sarcoma: diagnostic performance of (1)(8)F-FDG PET/CT versus conventional imaging for initial staging and follow-up. *AJR Am J Roentgenol*. 2015;204:153–60.
14. Skamene SR, Rakheja R, Dahlstrom KR, Roberge D, Nahal A, Charest M, Turcotte R, Hickeson M, Freeman C. Metabolic activity measured on PET/CT correlates with clinical outcomes in patients with limb and girdle sarcomas. *J Surg Oncol*. 2014;109:410–4.
15. Combemale P, Valeyrie-Allanore L, Giammarile F, Pinson S, Guillot B, Goulart DM, Wolkenstein P, Blay JY, Moggetti T. Utility of 18F-FDG PET with a semi-quantitative index in the detection of sarcomatous transformation in patients with neurofibromatosis type 1. *PLoS ONE*. 2014;9:e85954.
16. Casey DL, Wexler LH, Fox JJ, Dharmarajan KV, Schoder H, Price AN, Wolden SL. Predicting outcome in patients with rhabdomyosarcoma: role of [(18)f]fluorodeoxyglucose positron emission tomography. *Int J Radiat Oncol Biol Phys*. 2014;90:1136–42.
17. Nose H, Otsuka H, Otomi Y, Terazawa K, Takao S, Iwamoto S, Harada M. Correlations between F-18 FDG PET/CT and pathological findings in soft tissue lesions. *J Med Investig*. 2013;60:184–90.
18. Choi ES, Ha SG, Kim HS, Ha JH, Paeng JC, Han I. Total lesion glycolysis by 18F-FDG PET/CT is a reliable predictor of prognosis in soft-tissue sarcoma. *Eur J Nucl Med Mol Imaging*. 2013;40:1836–42.
19. Al-Ibraheem A, Buck AK, Benz MR, Rudert M, Beer AJ, Mansour A, Pomykala KL, Haller B, Juenger H, Scheidhauer K, Schwaiger M, Herrmann K. (18) F-fluorodeoxyglucose positron emission tomography/computed tomography for the detection of recurrent bone and soft tissue sarcoma. *Cancer*. 2013;119:1227–34.
20. Roberge D, Vakilian S, Alabed YZ, Turcotte RE, Freeman CR, Hickeson M. FDG PET/CT in initial staging of adult soft-tissue sarcoma. *Sarcoma*. 2012;2012:960194.
21. Payne MJ, Macpherson RE, Bradley KM, Hassan AB. Trabectedin in advanced high-grade uterine leiomyosarcoma: a case report illustrating the value of (18)FDG-PET-CT in assessing treatment response. *Case Rep Oncol*. 2014;7:132–8.
22. The Royal College Of R, Royal College Of Physicians Of L, Royal College Of P, Surgeons Of G, Royal College Of Physicians Of E, British Nuclear Medicine S, Administration Of Radioactive Substances Advisory C. Evidence-based indications for the use of PET-CT in the United Kingdom 2016. *Clin Radiol*. 2016;71:e171–88.
23. Rowland AF, Fazakerley DJ, James DE. Mapping insulin/GLUT4 circuitry. *Traffic*. 2011;12:672–81.
24. Thomas D, Henshaw R, Skubitz K, Chawla S, Staddon A, Blay JY, Roudier M, Smith J, Ye Z, Sohn W, Dansey R, Jun S. Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. *Lancet Oncol*. 2010;11:275–80.
25. Dimitrakopoulou-Strauss A, Strauss LG, Schwarzbach M, Burger C, Heichel T, Willeke F, Mechttersheimer G, Lehnert T. Dynamic PET 18F-FDG studies in patients with primary and recurrent soft-tissue sarcomas: impact on diagnosis and correlation with grading. *J Nucl Med*. 2001;42:713–20.
26. Bredella MA, Caputo GR, Steinbach LS. Value of FDG positron emission tomography in conjunction with MR imaging for evaluating therapy response in patients with musculoskeletal sarcomas. *AJR Am J Roentgenol*. 2002;179:1145–50.

Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at
www.biomedcentral.com/submit

